GILD/BMY—Based on the surprising YoY decline in 3Q12 Reyataz sales (#msg-80832233), it appears that GILD’s high pricing of Stribild is working out fine.
GILD and BMY have become fierce competitors in both HIV and HCV, even as they remain nominal partners on Atripla.
Market Data 
Markets 
AI
